Gain Therapeutics Inc. Common Stock (GANX)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings, honest accounting, and a margin of safety. Gain Therapeutics does not fit that mold. It is a 20-employee biotechnology company with no meaningful revenue; in fiscal 2023 it reported $55,180 of revenue, and in fiscal 2024 and fiscal 2025 revenue was not reported. It lost $22.3 million in fiscal 2023, $20.4 million in fiscal 2024, and $20.2 million in fiscal 2025. In the first half of fiscal 2026, filed results show net losses of $5.6 million in the quarter ended 2026-03-31 and $4.7 million in the quarter ended 2026-06-30. Trailing free cash flow was negative $19.0 million, a negative 30.8% yield on its $61.5 million market cap. The balance sheet has low debt—debt-to-equity of 0.05—but that only buys time; the Altman Z-score is -0.30 and Piotroski F-score is 0/9. Returns are deeply negative: ROE -268.3%, ROCE -95.5%. The stock trades at $1.41 as of 2026-10-13, near the bottom of its 52-week range of $1.40-$4.34. A P/B of 5.42 on a loss-making research firm offers no Graham-style cushion. The Magellan platform and GT-02287 may be scientifically interesting, but I cannot underwrite future cash flows without approved products, partnerships, or reliable revenue. This is not a business with a moat; it is a call option on clinical success. The FairStock score of 20/100 and Lynch category of none—because of losses in each of the last four years—match that view. I would need evidence of cash runway, trial progress, and eventual commercial validation before calling it an investment rather than a speculation.

In plain English: Gain Therapeutics is a small biotech company with about 20 employees trying to develop new medicines, especially its lead candidate GT-02287. It has no meaningful product revenue reported and has lost money for years, including a net loss of $20.2 million in fiscal 2025. At $1.41 a share, the price is near its 52-week low, but because there are no profits or meaningful sales, it is hard to call it cheap or expensive using ordinary business numbers; it looks like a high-risk research bet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer